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In January 2005, the United States (US) Food and Drug Administration 
(FDA) issued a public health advisory recommending against 
initiating nevirapine (NVP) in HIV-infected women (including 
pregnant women) with CD4 counts >250 cells/µl.1 The NVP package 
insert was revised accordingly to warn about risks, with further 
revision in November 2011 to comply with FDA recommendations 
on product labelling safety.2
The initial warning followed a meta-analysis of hepatotoxicity 
in over 600 women, stratified by CD4 count (risk ratio 9.8 with a 
CD4  count ≥250 cells/µl).3 However, results from several subsequent 
studies with larger datasets demonstrated no association between 
CD4 count and NVP toxicity.4-6 Current World Health Organization 
(WHO) guidelines recommend NVP as part of first-line antiretroviral 
therapy (ART) for pregnant women with CD4 ≤350 cells/µl,7 based 
on their own analysis of 836 pregnant women, which showed no 
increased hepatotoxicity risk at CD4 ≥250 cells/µl (relative risk 1.04; 
95% confidence interval (CI) 0.22 - 4.93).8 
The 2010 South African Prevention of Mother-to-Child 
Transmission (PMTCT) guidelines recommend lifelong NVP-based 
ART for HIV-infected pregnant women with WHO clinical stage 3 
or 4 disease, regardless of CD4 count.9 In contrast, the 2011 perinatal 
guidelines from the US Department of Health and Human Services 
recommend a protease inhibitor as part of the ART regimen for 
pregnant women with a CD4 count ≥250 cells/µl, while cautioning 
against starting NVP above this count.10 The British HIV Association 
2012 draft guidelines recommend either efavirenz (EFV) or NVP 
(with a CD4 count <250 cells/µl) or a boosted protease inhibitor 
as the third drug for pregnant women requiring ART for their own 
health.11 The recommendation of EFV is a departure from previous 
guidelines discouraging its use in pregnancy. Furthermore, women 
who conceived on EFV-based ART need not switch to another drug 
in the first trimester, following analysis of recent data showing no 
increased risk of birth defects after first-trimester EFV exposure.11
Reports of NVP-related maternal deaths have surfaced in South 
Africa, generating renewed concerns about the drug’s safety, notably 
among ART-naive pregnant women. The Eastern Cape Province 
recently amended its PMTCT guidelines following an analysis of 
45 HIV-related maternal deaths, 6 due to liver failure and Stevens-
Johnson Syndrome (SJS). The use of NVP in pregnancy since then 
has been limited to a single dose at delivery (M Shweni, personal 
communication). 
To address the uncertainty about the safety of initiating NVP-
based ART in pregnancy, we aimed to determine whether ART-naive 
pregnant women initiating NVP at higher CD4 counts experience 
greater toxicity. 
Methods
The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines were followed.12 All studies except 
case reports were evaluated for inclusion without consideration 
of their results. ART-naive pregnant women initiating NVP-based 
ART during the index pregnancy for maternal health or infant 
prophylaxis were included. For studies that included both ART-naive 
and -experienced pregnant women, only the data of ART-naive 
participants were extracted. ART-experienced pregnant women were 
excluded, including those naive to NVP. Combination ART studies 
which included NVP use for 7 days or longer were included only if 
liver transaminases at baseline were <1.25 times the upper limit of 
normal (ULN). For inclusion, women had to be followed up until 
delivery.
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Background. The package insert for nevirapine (NVP) cautions 
against use in HIV-infected women (including pregnant women) 
with CD4 counts ≥250 cells/µl. However, recent studies showed that 
the CD4 count of pregnant women receiving antiretroviral therapy 
(ART) was not predictive of NVP toxicity.
Objectives. To determine whether ART-naive pregnant women 
initiating NVP-based ART at higher CD4 counts experience greater 
toxicity compared with pregnant women at lower CD4 counts.
Methods. We reviewed studies comparing serious adverse NVP-
related events among ART-naive pregnant women who commenced 
therapy at higher v. lower CD4 counts. Relevant studies were 
extracted from PubMed, SCOPUS and EMBASE, major journals 
and conference proceedings prior to December 2011. Authors were 
contacted for additional data. Data were independently extracted 
and entered into Review Manager.
Results. Fourteen studies (2 663 participants) were included 
for analysis. The odds ratio (OR) for overall NVP toxicity 
among pregnant women with CD4 <250 cells/µl was 0.61 (95% 
confidence interval (CI) 0.43 - 0.85). When analysis was restricted 
to prospective studies only (7 studies, 1 318 participants), the results 
were consistent for overall NVP toxicity (OR 0.43; 95% CI 0.25 - 
0.73) and severe hepatotoxicity (OR 0.45; 95% CI 0.22 - 0.90), but 
not for severe cutaneous reaction (OR 0.53; 95% CI 0.26 - 1.10).
Conclusion. Initiating NVP-based ART during pregnancy at 
CD4 ≥250 cells/µl increases toxicity risk and should be avoided, 
necessitating urgent revision of current guidelines supporting this 
practice.
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The primary outcome measure was overall NVP toxicity (severe 
hepatotoxicity and severe cutaneous reaction). National Institutes of 
Health Division of AIDS (NIH-DAIDS) guidelines13 were followed 
for grading severity. Severe hepatotoxicity was defined as: grade 3 or 4 
elevation of liver transaminases (>5 and >10 times ULN, respectively); 
rash-associated hepatotoxicity; or clinical hepatitis accompanied by 
elevated liver transaminases. Severe cutaneous reaction was defined 
as: diffuse maculopapular rash with vesicles, limited number of 
bullae or superficial ulceration of mucous membranes limited to one 
site (grade 3); or the presence of generalised bullous lesions, SJS, or 
toxic epidermal necrolysis (grade 4). Cases of concurrent rash and 
hepatotoxicity were assigned to ‘severe hepatotoxicity’.
We performed electronic searches of PubMed, SCOPUS and 
EMBASE from inception to 25 November, 5 December and 31 
December 2011, respectively. Search terms used included ‘nevirapine’ 
and ‘pregnancy or pregnant’ and ‘toxicity or safety or adverse effects 
or side-effects’. An extensive hand-search of major infectious diseases 
journals published prior to December 2011 was performed. Article 
reference lists and AIDS conference proceedings were also hand-
searched.
Abstracts were reviewed and potentially relevant full-text articles 
were retrieved based on consensus and discussion. All articles from 
the WHO meta-analysis which included pregnant women were also 
retrieved. Data were extracted using a previously prepared data 
extraction form. For duplicate publications, the more informative 
study was used. Authors from 13 articles were contacted for additional 
data or clarity regarding datasets; 9 responded.
Review Manager 5.1 (RevMan 2011) was used for statistical 
analyses. The Mantel-Haenszel method was used for comparisons 
of dichotomous data. Results were presented as odds ratios (ORs) 
with 95% CIs. Heterogeneity was quantified using the I2 statistic (the 
proportion of variation due to study heterogeneity).14 In the absence 
of substantial heterogeneity (I2<30%) results were pooled using a 
fixed-effects model. Funnel plots were visually examined to explore 
possible publication bias.
Results
Data retrieval, exclusion and inclusion are summarised in Fig. 1. We 
excluded some of the largest studies on PMTCT (including several 
thousand women from around the globe) primarily because NVP 
use was restricted to women with CD4 counts <250 cells/µl.15,16 In 
many of these studies, toxicity data were not routinely collected (C 
Townsend, personal communication). Routine collection of toxicity 
data was also absent in a number of African PMTCT studies with 
fairly large cohorts. 
Among reasons for the exclusion of certain antenatal studies 
(Table 1),6,15-26 the most common reason was the absence of data 
dichotomised by CD4 count. Two studies with CD4 cut-offs of 500 
Table 1. Characteristics of excluded studies
Author Year Participants (N) ART-naive (n) Details
Bersoff-Matcha17 2010 253 42 No CD4 data 
No SAEs
Black18 2008 689 509 No CD4 stratification data
Mean CD4: 154
Skin rashes: 16 
Liver toxicity: 1%
Bottaro19 2010 1 110 118 No CD4 stratification data
LEE: 3 
Rash: 6 (0 in ART-experienced)
ECS15 2006 5 967 1 279 No toxicity data
NVP use at CD4 <250
Edwards20 2001 46 33 No CD4 data
SAEs: 4
Joao21 2006 611 197 No CD4 stratification data; 2 SAEs (CD4 counts 295 
and 406)
Kramer22 2004 125 125 CD4 stratified at 500
SAEs: 3 
Mean CD4 among SAEs: 321
Manfredi23 2007 27 4 No data of ART-naive pregnancies
Ouyang24 2009 2 050 N/R Could not extract data of ART-naive women
Ouyang6 2010 1 229 91 Could not extract data of ART-naive women
Timmermans25 2005 453 58 CD4 <200 to >500
LEE = >3 x ULN
SAEs: 11 
Mean CD4 among LEE: 307
Townsend16 2008 5 930 1 959 No toxicity data
NVP use at CD4 <250
Weinberg26 2011 117 19 No CD4 data
SAEs: 3
LEE = liver enzyme elevation; SAE = serious adverse event; ULN = upper limit of normal.
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and 200 cells/µl, respectively,22,25 were also excluded as CD4 count 
relative to NVP toxicity was not available.
At data entry, we excluded 1 of 5 serious adverse events (SAEs) 
reported by Hitti et al.,27 as the subject (CD4 count 259 cells/µl) 
reportedly developed clinical hepatitis, but alanine transaminase (ALT) 
was 41 U/l at diagnosis. Three further participants were excluded from 
the data of Natarajan et al.;28 
CD4 counts were unknown in 
2, and the third (CD4 count 
332 cells/µl) developed elevated 
liver transaminases >3 times the 
ULN. From Peters et al., we only 
extracted the data for the women 
who initiated NVP-based ART.29
Fourteen studies were 
reviewed, including a total of 
2 663 participants (Table 2).4,5,27-
38 One study was funded by the 
NVP manufacturer Boehringer 
Ingelheim.30 The studies, mostly 
undertaken between 2001 and 
2006, were predominantly 
observational with participant 
numbers ranging from 17 to 
703. Average female participant 
age was 28 years, and ART 
was initiated at an average of 
27 weeks’ gestation. The mean 
baseline CD4 count varied (113 
- 545 cells/µl). Participants with 
hepatitis B or C infection were 
excluded from 2 studies,4,27 
whereas 7 studies reported 
the prevalence of hepatitis 
co-infection.28-30,34,36-38 NVP was 
initially commenced at 200 mg 
daily for 14 days in all women. The CD4 cut-off was 250 cells/µl for 
toxicity analyses in all studies, except for one (CD4 cut-off of 200 cells/
µl).35 Mean time to toxicity ranged from 27 to 74 days. The overall 
frequency of NVP toxicity was 8.3%, driven mostly by hepatotoxicity. 
Additional unpublished data were obtained from Coffie et al.,31 
Lyons et al.36 and Marazzi et al.5 There was a significant reduction in 
Table 2. Description of included studies
Author Year
ART-naive 







Aaron30 2010 79 USA 1999 - 2005 Retrospective 42 2 6 N/R
Coffie31 2010 125 Cote d’Ivoire 2003 - 2006 Prospective 58 5 3 6
Gonzales32 2004 170 USA 1997 - 2003 Retrospective N/R 6 5 0
Hitti27 2004 17 USA 2003 - 2004 Randomised 63 3 1 1
Jamisse33 2007 146 Mozambique 2004 - 2005 Prospective 36 4 4 0
Joy34 2005 22 USA 2001 - 2005 Retrospective 42 3 0 0
Kilewo35 2009 429 Tanzania 2004 - 2006 Prospective N/R 2 7 0
Kondo4 2007 133 Brazil 2003 - 2006 Retrospective 27 2 21 0
Lyons36 2006 85 Ireland 2000 - 2003 Retrospective 32 8 1 2
Marazzi5 2006 703 Mozambique 2002 - 2004 Retrospective 74 46 25 5
Natarajan28 2007 153 UK 1997 - 2003 Retrospective 42 5 6 0
Peters29 2011 310 Kenya 2003 - 2006 Prospective 68 12 16 0
Phanuphak37 2007 244 Thailand N/R Prospective 42 15 9 0
Van Schalkwyk38 2008 47 Canada 2001 - 2005 Prospective 33 3 1 0
Total 2 663 116 105 14
ART-naive = number of ART-naive pregnant women who initiated NVP-based ART; TTT = time to toxicity (days); Liver = severe hepatotoxicity; Skin = severe cutaneous reaction; N/R = not 
reported.
Fig. 1. Identification, retrieval and exclusion/inclusion of studies in this analysis. pKa = pharmacokinetic analysis; 
PMTCT = prevention of mother-to-child transmission; sd-NVP = single dose nevirapine.
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overall NVP toxicity among women with CD4 <250 cells/µl (OR 0.61; 
95% CI 0.43 - 0.85; I2 8%). One study35 was excluded from analysis 
as it used a CD4 cut-off of 200 cells/µl; the result following exclusion 
was unaltered (OR 0.62; 95% CI 0.44 - 0.87; I2 12%). 
Severe hepatotoxicity was not significantly reduced with NVP 
use at CD4 <250 cells/µl (OR 0.75; 95% CI 0.48 - 1.15; I2 0%). Risk 
for severe cutaneous reaction was analysed from 13 studies (2  572 
participants). There was a statistically significant reduction in severe 
skin rash among pregnant women with CD4 <250 cells/µl (OR 0.57; 
95% CI 0.35 - 0.94; I2 0%).
All studies except Aaron et al. included mortality data.30 The 
cumulative mortality rate was 0.5% (14 of 2 584 women), with at least 
4 maternal deaths directly attributable to NVP use.5,27,36 We could not 
perform an NVP-related mortality analysis stratified by CD4 count 
due to data limitations.
For the 7 prospective studies reviewed, involving 1 318 participants, 
the OR for overall NVP toxicity among women with CD4 <250 
cells/µl was 0.43 (95% CI 0.25 - 0.73; I2 0%), and 0.45 for severe 
hepatotoxicity (95% CI 0.22 - 0.90; I2 0%). NVP use at CD4 <250 
cells/µl did not significantly reduce the odds of severe cutaneous 
reaction (OR 0.53; 95% CI 0.26 - 1.10; I2 0%).
The Funnel plot (Fig. 2) showed no gross asymmetry to suggest 
overt publication bias.
Discussion
Commencing NVP in ART-naive pregnant women with CD4 counts 
≥250 cells/µl significantly increased the odds of toxicity. Our results 
are consistent with the findings of a previous meta-analysis that 
informed the current FDA safety alert on NVP use.3 An important 
finding of our review was that NVP-related SAEs seem to occur 
fairly soon after ART initiation (within 10 weeks). Relative risks 
of toxicity may be lower than previously estimated. For every 200 
women who commenced NVP-based ART at CD4 ≥250 cells/µl, 7 
additional women experienced severe side-effects. Strengths of our 
review include the size of the dataset (the largest to date), robust 
methods, and that most included studies were published after the 
FDA advisory in 2005.
Our results vary with those of several recently published studies on 
the risks of NVP-related toxicity in pregnancy, for which there may be 
numerous reasons. Firstly, in many studies the toxicity data of ART-
naive and -experienced pregnant women were combined.6,19,23,24 The 
appropriateness of combining such data deserves scrutiny. Mocroft et 
al. demonstrated that the risk of NVP discontinuation due to toxicity 
was significantly lower in ART-experienced women compared with 
ART-naive women at CD4 counts ≥250 cells/µl.39 In another study, 
stable virologically suppressed women who switched to NVP-based 
ART did not experience higher rates of hepatotoxicity.40 Complete 
plasma viral load suppression appears to be protective of NVP 
hepatotoxicity. These findings suggest that combining data of ART-
naive and -experienced women may underestimate the true risks of 
NVP toxicity. For example, in the analysis by Ouyang et al., only 91 
of 1 229 pregnant women were ART-naive and initiated NVP-based 
ART, suggesting that the majority of women were already taking ART 
at conception.6 In their study, the rate of severe hepatotoxicity was 
0.5%. A separate analysis comparing ART-naive and -experienced 
women was not performed. Also, the median time from ART 
initiation to toxicity was 163 days, considerably longer than the time 
reported by studies in our review.
Secondly, in some of the recently published studies the data on 
hepatotoxicity – stratified by CD4 count – were performed as a single 
analysis for women on NVP and those on nelfinavir (NFV).24,29,30 
Nelfinavir use is rarely associated with hepatotoxicity.11 Combining 
hepatotoxicity data for NFV and NVP may potentially dilute the 
association between NVP and hepatotoxicity at higher CD4 counts. 
As an example, in the study by Peters et al.,29 only 1 of 208 women 
with CD4 ≥250 cells/µl initiated NVP during the second enrolment 
period. The remaining 207 women started NFV. An analysis of 
adverse events for the second period adjusted for CD4 count may not 
have been appropriate.
Thirdly, the endpoints in our systematic review were limited to 
severe or life-threatening adverse events. Several papers included 
comparisons of all NIH-DAIDS grades of toxicity.4,5,28,30,33,35-38 In 
the WHO meta-analysis, the authors did not evaluate cutaneous 
reactions in pregnancy, and NVP hepatotoxicity was analysed for 
all grades of severity.8 They correctly emphasised the need for 
cautious interpretation of their results based only on grades 3 and 4 
toxicities, given limited cohort numbers and open-labelled designs 
of included studies. However, 3 important studies considered in 
their meta-analysis merit discussion. In the study by Jamisse et 
al.,33 the overall rates of hepatotoxicity among women with CD4 
counts lower and higher than 250 cells/µl were similar (6% and 
9%, respectively), but severe hepatotoxicity occurred in 0% and 6% 
(p=0.02) in the 2 groups, respectively. In the study by Kondo et al.,4 
severe hepatotoxicity occurred exclusively in women with CD4 ≥250 
cells/µl. The study by Marazzi et al. showed no differences in grade 
3 and 4 hepatotoxicity rates by CD4 count (250 cells/µl), but their 
unpublished results for severe cutaneous reaction among women 
with CD4 counts less or greater than 250 cells/µl, were 2% and 4%, 
respectively.5 While we certainly share the WHO authors’ concerns 
around the interpretation of results based on limited numbers, their 
meta-analysis did not provide reassurance on treatment-limiting 
toxicities above this CD4 threshold.
It remains unclear why women with better immunological reserves 
are more vulnerable to the hazards of NVP. The mechanism is 
believed to be an immune-mediated hypersensitivity reaction. Some 
investigators have found a higher frequency of allele HLA-DRB1*01 
in patients who developed a cutaneous reaction to NVP or EFV.41 
Others demonstrated increased expression of HLA-Cw8 among 
those who developed NVP hypersensitivity.42 In a case-control 
study performed in South Africa, investigators found that the 
MDR1 position 3435 T allele was associated with a decreased risk 
of NVP-related hepatotoxicity.43 A recent systematic review showed 
that pregnancy itself may be an additional risk factor for NVP 
hepatotoxicity.44 Predisposition to NVP toxicity may be multifactorial 
and, at present, there is no simple reliable way to predict such 
outcomes among women initiating NVP-based ART.
Fig. 2. Funnel plot of overall NVP toxicity from studies included in the 
review.
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Study limitations
A number of studies did not report the use of drugs with overlapping 
toxicity profiles (e.g. rifampicin, isoniazid and cotrimoxazole). The 
reporting of hepatitis B and C and alcohol and illicit drug use 
varied considerably, and few studies reported the prevalence of pre-
eclampsia and HELLP syndrome in pregnancy. The latter is known to 
mimic drug toxicity and lead to NVP withdrawal. 
Finally, only one study was a randomised trial, and it was 
prematurely terminated.27 All others were observational, and therefore 
prone to several forms of bias. Confounding variables which cannot 
be measured are usually addressed through random allocation of 
participants to an intervention arm. A randomised study comparing 
NVP with EFV during pregnancy seems to be the way forward, but is 
unlikely to receive ethics approval until the ‘teratogenicity’ concerns 
surrounding EFV use in pregnancy are resolved.
Conclusion
We observed an absence of new data to support the safe initiation 
of NVP among ART-naive pregnant women with a CD4 count 
≥250 cells/µl. Rather, NVP initiation in these women significantly 
increased the frequency of SAEs. We strongly recommend urgent 
revision of guidelines supporting this practice. Pharmacovigilance 
programmes on ART use in pregnancy should be strengthened 
nationally. 
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